Delivery of Adipose Derived Stem Cells for Healing Surgical Hernia Repairs

递送脂肪干细胞用于治愈疝气修复手术

• 批准号: 8198653
• 负责人: Bruce Lamb
• 金额: $ 7.31万
• 依托单位: AFFINERGY ,INC
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-10 至 2011-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8198653
• 关键词: Abdomen; Accounting; Address; Adipose tissue; Affinity; Autologous; Bacteriophages; Binding; Biocompatible; Biocompatible Materials; Biomechanics; Bioprosthesis device; Blood Vessels; Caring; Cell Therapy; Cells; Chemistry; Clinical; Dermal; Distress; Ensure; Fascia; Foreign Bodies; Fracture; Goals; Growth Factor; Healed; Hernia; Infection prevention; Injury; Inpatients; Lead; Left; Link; Mechanics; Mediating; Myocardial; Operative Surgical Procedures; Outcome; Pain; Patients; Peptides; Phage Display; Pharmaceutical Preparations; Phase; Phenotype; Property; Recurrence; Safety; Screening procedure; Site; Specificity; Stem cells; Surgeon; Suture Techniques; Technology; Testing; Time; Tissues; United States; Ursidae Family; Vascularization; Visceral; Wound Healing; abdominal wall; base; commercialization; cost; design; follow-up; healing; improved; in vivo; novel; novel therapeutic intervention; paracrine; point of care; prevent; programs; protein aminoacid sequence; prototype; reconstruction; repaired; soft tissue; success; synthetic peptide

DESCRIPTION (provided by applicant): Over 700,000 surgical hernia repairs are performed each year in the United States and despite recent advances, a significant rate of recurrence persists. Incisional or visceral hernia repairs account for 100,000 of these surgeries costing 1.7B annually, and have a recurrence rate of 25% for an initial repair and 44% after a second repair. The incorporation of biocompatible mesh to strengthen the abdominal fascia has largely replaced high-tension suturing techniques in surgical hernia repair. Currently, the preferred biomaterials include durable synthetic mesh, which bears all the pitfalls of a permanent foreign body; absorbable mesh which does not provide enough long-term support; or bioprosthetics, which are bioabsorbable but fail at an unacceptably high rate causing recurrent hernias. Surgeons are therefore left to choose between a foreign body and a weak repair. Our goal is to accelerate healing rates after hernia repair by using bioprosthetics containing adipose-derived stem cells (ASCs). ASCs were identified in 2001, and have been used for cell therapy in many indications including bone fractures, myocardial repair and soft tissue repair. Their prohealing function is largely mediated through paracrine factors secreted at the site of injury to promote vascularization, and tissue remodeling. The product prototype we envision will be a point-of-care ASC seeded bioprosthetic that will promote faster healing times, prevent infection, and leave a biologic repair. Our bioprosthetic is designed to prevent recurrence of incisional hernias, thereby reducing inpatient follow-up care, additional surgeries, and patient distress. PUBLIC HEALTH RELEVANCE: Improving the rate of healing after surgical hernia repair will reduce pain, discomfort and follow-up care. The introduction of biologics into soft tissue healing represents a potential improvement for surgical procedures, but due to a lack of clinically viable delivery mechanisms, these strategies remain under utilized. This proposal will develop a novel bioprosthetic for the local retention of cells to improve healing rates and reduce recurrence of incisional hernia repairs. Because hernia repair is one of the most common surgical procedures world-wide, with more than 700,000 surgeries in the United States, this product will provide substantially improved clinical outcomes for a large number of patients.

描述（由申请人提供）：在美国，每年进行700,000多个手术疝修理，尽管最近进展，但复发率仍然很高。切开或内脏的疝修理量为每年1.7B的手术中有100,000个，初始维修的复发率为25％，在第二次维修后的重复率为44％。生物相容性的网格掺入以增强腹部筋膜，在很大程度上取代了手术疝修复中的高张紧缝合技术。当前，首​​选的生物材料包括耐用的合成网，它具有永久异物的所有陷阱。可吸收的网格，无法提供足够的长期支持；或生物植物，可生物吸收，但以不可接受的高率失败，导致复发性疝气。因此，外科医生可以在异物和弱修复之间进行选择。我们的目标是通过使用含有脂肪衍生的干细胞（ASC）的生物植物来加速疝气修复后的愈合率。 ASC在2001年被鉴定出来，并已在许多适应症中用于细胞治疗，包括骨折，心肌修复和软组织修复。它们的促进功能在很大程度上是通过在损伤部位分泌的旁分泌因子介导的，以促进血管化和组织重塑。我们设想的产品原型将是一种护理点ASC种子生物假体，它将促进更快的愈合时间，防止感染并留下生物学修复。我们的生物假体旨在防止切开的疝气复发，从而减少住院随访，额外的手术和患者的困扰。 公共卫生相关性：改善手术疝修复后的愈合率将减轻疼痛，不适和随访护理。将生物制剂引入软组织愈合是手术程序的潜在改进，但是由于缺乏临床可行的递送机制，这些策略仍在利用中。该提案将开发出一种新型的生物假体，用于细胞的局部保留，以提高愈合率并减少切开的疝气修复的复发。由于疝气修复是全球最常见的外科手术之一，在美国进行了70万多个手术，因此该产品将为大量患者提供大幅改善的临床结果。